Tyk2 inhibitors for the treatment of inflammatory bowel disease.
CL202600817A1Pending Publication Date: 2026-07-10TAKEDA PHARMA CO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CL202600817
- Authority / Receiving Office
- CL · CL
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-09-20
- Filing Date
- 2026-03-19
- Publication Date
- 2026-07-10
Abstract
A method for treating inflammatory bowel disease, including Crohn's disease or ulcerative colitis, in a patient in need, consisting of administering to the patient a therapeutically effective amount of compound 1 (N-((1R,2R)-2-methoxycyclobutyl)-7-(methylamino)-5-((2-oxo-2H-[1,2'-bipyridin]-3-yl)amino)pyrazolo[1,5-a]pyrimidine-3-carboxamide).
Need to check novelty before this filing date? Find Prior Art